×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABBV – abbvie inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABBV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/9
04:59 am
abbv
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn's Disease [Yahoo! Finance]
Low
Report
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn's Disease [Yahoo! Finance]
3/5
09:20 pm
abbv
???????????????????? : ????????:2035????1856?9000??????????CAGR17.9%???????????????????? [CNET News]
Low
Report
???????????????????? : ????????:2035????1856?9000??????????CAGR17.9%???????????????????? [CNET News]
3/4
09:21 am
abbv
AbbVie: The Only Big Pharma Stock I'd Consider a Buy-and-Never-Sell [Yahoo! Finance]
Low
Report
AbbVie: The Only Big Pharma Stock I'd Consider a Buy-and-Never-Sell [Yahoo! Finance]
3/4
08:00 am
abbv
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
Low
Report
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
3/3
01:30 pm
abbv
OSE narrows pipeline focus amid Boehringer MASH collaboration retreat [Yahoo! Finance]
Low
Report
OSE narrows pipeline focus amid Boehringer MASH collaboration retreat [Yahoo! Finance]
3/3
08:23 am
abbv
AbbVie to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Low
Report
AbbVie to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
3/3
08:00 am
abbv
AbbVie to Present at the Leerink Partners Global Healthcare Conference
Low
Report
AbbVie to Present at the Leerink Partners Global Healthcare Conference
3/2
08:31 pm
abbv
AbbVie's New Data And Approval Test Growth And Valuation Story [Yahoo! Finance]
Low
Report
AbbVie's New Data And Approval Test Growth And Valuation Story [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/6
05:06 pm
abbv
Form 4 AbbVie Inc. For: Mar 04 Filed by: Purdue David Ryan
Low
Report
Form 4 AbbVie Inc. For: Mar 04 Filed by: Purdue David Ryan
3/6
05:05 pm
abbv
Form 144 AbbVie Inc. Filed by: Purdue David Ryan
Low
Report
Form 144 AbbVie Inc. Filed by: Purdue David Ryan
3/6
05:02 pm
abbv
Form 4 AbbVie Inc. For: Feb 27 Filed by: Crum Demetris D
Low
Report
Form 4 AbbVie Inc. For: Feb 27 Filed by: Crum Demetris D
3/4
05:00 pm
abbv
Form 8-K AbbVie Inc. For: Mar 04
Low
Report
Form 8-K AbbVie Inc. For: Mar 04
3/3
06:15 pm
abbv
Form 4 AbbVie Inc. For: Feb 27 Filed by: Thakkar Roopal
Low
Report
Form 4 AbbVie Inc. For: Feb 27 Filed by: Thakkar Roopal
3/3
06:12 pm
abbv
Form 4 AbbVie Inc. For: Feb 27 Filed by: Michael Robert A.
Low
Report
Form 4 AbbVie Inc. For: Feb 27 Filed by: Michael Robert A.
3/3
06:10 pm
abbv
Form 4 AbbVie Inc. For: Feb 27 Filed by: Siatis Perry C
Low
Report
Form 4 AbbVie Inc. For: Feb 27 Filed by: Siatis Perry C
3/3
06:10 pm
abbv
Form 4 AbbVie Inc. For: Feb 27 Filed by: Reents Scott T
Low
Report
Form 4 AbbVie Inc. For: Feb 27 Filed by: Reents Scott T
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/26
Form PX14A6G AbbVie Inc. Filed by: United Church Funds, Inc.
9.7%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
TOP News Decliners
6/25
AbbVie nears deal to buy Allergan for more than $60 bln - WSJ [Reuters]
-11.8%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: